These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 29375124)

  • 1. IDO1 in cancer: a Gemini of immune checkpoints.
    Zhai L; Ladomersky E; Lenzen A; Nguyen B; Patel R; Lauing KL; Wu M; Wainwright DA
    Cell Mol Immunol; 2018 May; 15(5):447-457. PubMed ID: 29375124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of IDO in brain tumor immunotherapy.
    Zhai L; Lauing KL; Chang AL; Dey M; Qian J; Cheng Y; Lesniak MS; Wainwright DA
    J Neurooncol; 2015 Jul; 123(3):395-403. PubMed ID: 25519303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
    Kim M; Tomek P
    Front Immunol; 2021; 12():636081. PubMed ID: 33708223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
    Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
    Front Immunol; 2021; 12():800630. PubMed ID: 35003126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
    Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
    Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer.
    Passarelli A; Pisano C; Cecere SC; Di Napoli M; Rossetti S; Tambaro R; Ventriglia J; Gherardi F; Iannacone E; Venanzio SS; Fiore F; Bartoletti M; Scognamiglio G; Califano D; Pignata S
    Front Immunol; 2022; 13():953115. PubMed ID: 36119020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
    Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
    Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges.
    Peng X; Zhao Z; Liu L; Bai L; Tong R; Yang H; Zhong L
    Drug Des Devel Ther; 2022; 16():2639-2657. PubMed ID: 35965963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
    Peyraud F; Guegan JP; Bodet D; Cousin S; Bessede A; Italiano A
    Front Immunol; 2022; 13():807271. PubMed ID: 35173722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
    Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
    Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression.
    Amobi A; Qian F; Lugade AA; Odunsi K
    Adv Exp Med Biol; 2017; 1036():129-144. PubMed ID: 29275469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
    Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
    Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
    Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
    Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies.
    Hosseinalizadeh H; Mahmoodpour M; Samadani AA; Roudkenar MH
    Med Oncol; 2022 Jun; 39(9):130. PubMed ID: 35716323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.
    Huang Q; Xia J; Wang L; Wang X; Ma X; Deng Q; Lu Y; Kumar M; Zhou Z; Li L; Zeng Z; Young KH; Yi Q; Zhang M; Li Y
    J Hematol Oncol; 2018 Apr; 11(1):58. PubMed ID: 29685162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies.
    Zhai L; Bell A; Ladomersky E; Lauing KL; Bollu L; Sosman JA; Zhang B; Wu JD; Miller SD; Meeks JJ; Lukas RV; Wyatt E; Doglio L; Schiltz GE; McCusker RH; Wainwright DA
    Front Immunol; 2020; 11():1185. PubMed ID: 32612606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
    Zhai L; Ladomersky E; Dostal CR; Lauing KL; Swoap K; Billingham LK; Gritsina G; Wu M; McCusker RH; Binder DC; Wainwright DA
    Brain Behav Immun; 2017 May; 62():24-29. PubMed ID: 28179106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies.
    Jiang K; Wang Q; Chen XL; Wang X; Gu X; Feng S; Wu J; Shang H; Ba X; Zhang Y; Tang K
    Int J Nanomedicine; 2024; 19():8847-8882. PubMed ID: 39220190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
    Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
    Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0.
    Grobben Y; de Man J; van Doornmalen AM; Muller M; Willemsen-Seegers N; Vu-Pham D; Mulder WR; Prinsen MBW; de Wit J; Sterrenburg JG; van Cauter F; den Ouden JE; van Altena AM; Massuger LF; Uitdehaag JCM; Buijsman RC; Zaman GJR
    Front Immunol; 2020; 11():609490. PubMed ID: 33584686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.